Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1538 • 2013 ACR/ARHP Annual Meeting
The Age At Onset Of Symptoms Influence The Clinical Expression Of The Disease In Patients With Ankylosing Spondylitis
Natalia Zamora¹, Emilce Edith Schneeberger¹, Luis Alejandro Cayetti², Fernando Sommerfleck¹ and Gustavo Citera¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: The onset of symptoms before 10 years and after 40 years is uncommon in patients with ankylosing spondylitis (AS). Some authors have found specific…
Abstract Number: 1033 • 2013 ACR/ARHP Annual Meeting
Psychological status correlates of disease activity and sleep quality in patients with Ankylosing Spondylitis: A case-control study
Mingcan Yang¹, Yutong Jiang², Zhiming Lin³, Zetao Liao⁴, Qiuxia Li⁴, Yanli Zhang¹ and Jieruo Gu⁵, ¹Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Rheumatology, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, ³Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ⁴Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁵Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: The objective of this study was to compare psychological status and sleep quality between the patients with AS patients and healthy controls, and to discover the correlation between anxiety, depression and sleep disturbances, to evaluate the associated factors of disease specific variables in AS patients and to detect independent factors contributing to psychological variables. Methods: A nationwide face-to-face epidemiological investigation was performed in multiple centers of China. The demographic data , clinical symptoms/signs and psychological assessment data including Zung self-rating anxiety scale (SAS), Zung self-rating depression scale (SDS) and the Pittsburgh Sleep Quality Index questionnaire (PSQI) were collected using questionnaires. Mann-Whitney U test and t test was used in independent groups for parametric variables, whereas the Spearman correlation analysis and multiple stepwise regression analysis were used to assess correlation between parametric variables. Results: 683 AS patients by the revised New York criteria for AS and 697 age-, sex-, education-matched healthy controls were enrolled in the study.(1) Compared with healthy controls, AS patients suffered from more severe psychological disorders and sleep disturbance（P
Abstract Number: 2810 • 2013 ACR/ARHP Annual Meeting
Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists
Chan-Nam Son¹, Tae-Hwan Kim², Il-Hoon Sung³, Jae-Bum Jun² and Dae-Hyun Yoo², ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor alpha (Anti-TNFα) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis…
Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Trayton Mains¹ and Vikas Majithia², ¹University of Mississippi Medical Center, Jackson, MS, ²G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…
Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting
Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée M. van der Heijde³, Maxime Dougados⁴, Philip Mease⁵, John D. Reveille⁶, Jessica Walsh⁷, Alan J. Kivitz⁸, Walter P. Maksymowych⁹, Jürgen Braun¹⁰, Atul A. Deodhar¹¹, Christian Stach¹², Bengt Hoepken¹², Pritibha Singh¹² and Joachim Sieper¹³, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Utah Hospital, Salt Lake City, UT, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ¹¹Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR, ¹²UCB Pharma, Monheim, Germany, ¹³Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…
Abstract Number: 1505 • 2013 ACR/ARHP Annual Meeting
Evaluation Of a Case Ascertainment Tool For Ankylosing Spondylitis and Axial Spondylarthritis Among All Referrals To General Rheumatology Clinics
Eswar Krishnan¹, Michael H. Weisman², Atul A. Deodhar³, Linjun Chen¹ and Lianne S. Gensler⁴, ¹Medicine, Stanford University, Palo Alto, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Several strategies for distinguishing Ankylosing Spondylitis (AS) and Axial Spondylarthritis (axSpA) from other conditions have been proposed but have only been studied in the…
Abstract Number: 1015 • 2013 ACR/ARHP Annual Meeting
Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Ankylosing Spondylitis Patients In The Czech Republic
Liliana Sedova^1,2, Jiri Stolfa^1,2, David Suchy³, Andrea Smrzova⁴, Jiri Klimes⁵, Milan Vocelka⁵ and Tomas Dolezal⁵, ¹Institute of Rheumatology, Prague, Czech Republic, ²Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, ³Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, ⁴3rd internal clinic, University hospital Olomouc, Olomouc, Czech Republic, ⁵Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic
Background/Purpose: Our aim was to describe the quality-of-life (QoL), productivity impairment, clinical indicators and health care costs in relationship to functional status described by Bath…
Abstract Number: 1825 • 2012 ACR/ARHP Annual Meeting
Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities
Chanseok Rhee¹, Janet E. Pope², Andrew E. Thompson³, Nicole G. H. Le Riche⁴, Gina Rohekar⁵ and Sherry Rohekar⁵, ¹School of Medicine and Dentistry, Schulich School of Medicine and Dentisty, Western University, London, ON, Canada, ²Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ³Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ⁴Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, London, ON, Canada
Background/Purpose: Few studies directly compare work disability (WD) and work productivity losses in different forms of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1349 • 2012 ACR/ARHP Annual Meeting
Trends in Incidence and Clinical Features of Ankylosing Spondylitis in Olmsted County (1980-2009): A Population Based Study
Kerry Wright¹, Cynthia S. Crowson², Clement J. Michet¹ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: To determine trends in the incidence and clinical presentation of ankylosing spondylitis (AS) among residents of a geographically defined area first diagnosed 1980-2009 and…
Abstract Number: 586 • 2012 ACR/ARHP Annual Meeting
High Prevalence of Anti-CD-74 Antibodies with Specificity for the Class II-Associated Invariant Chain Peptide in Patients with Axial Spondyloarthritis but Not in Controls
Xenofon Baraliakos¹, Niklas T. Baerlecken², Frank Heldmann³, Torsten Witte⁴ and Jürgen Braun³, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany
Background/Purpose: The pathogenesis of axial spondyloarthritis (axSpA) is still unclear. Based on the strong association with HLA-B27 and ERAP-1, T cells are believed to play…
Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Elisabeth Lie¹, Karen M. Fagerli², Knut Mikkelsen³, Åse S. Lexberg⁴, Erik Rødevand⁵, Till Uhlig¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, Oslo, Norway, ³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…
Abstract Number: 1352 • 2012 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis
J. Christiaan van Denderen¹, Ingrid M. Visman¹, M. T. Nurmohamed², Maria S.A. Suttorp-Schulten³ and Irene E. van der Horst-Bruinsma⁴, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ³Ophtalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose : A high percentage (30-40%) of patients with Ankylosing Spondylitis (AS) suffer from acute anterior uveitis (AAU) attacks. Local treatment with corticosteroids is a…
Abstract Number: 587 • 2012 ACR/ARHP Annual Meeting
Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis
Q. Wu¹, Robert D. Inman² and Karen Davis³, ¹Research, Toronto Western Research Institute, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Department of Surgery, Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: The mechanisms underlying pain in ankylosing spondylitis (AS) are unclear. The aim of this study was to investigate whether there is a neuropathic component…
Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Alper M. van Sijl¹, Izhar C. van Eijk², Mike J.L. Peters³, Erik H. Serne³, Yvo M. Smulders⁴ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…
Abstract Number: 987 • 2012 ACR/ARHP Annual Meeting
Autoimmune Susceptibility Genes Are Regulators of Gene Expression Response to ER Stress
William E. Bernal¹, Michael P. Morley² and Vivian G. Cheung³, ¹Division of Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Pediatrics & Genetics, Howard Hughes Medical Institute, Chevy Chase, MD; University of Pennsylvania, Philadelphia, PA
Background/Purpose: Endoplasmic recticulum (ER) stress is caused by excessive demands on the protein-processing capacity of the ER; inefficiencies in response to ER stress lead to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.